0000903423-14-000118.txt : 20140220
0000903423-14-000118.hdr.sgml : 20140220
20140220185653
ACCESSION NUMBER: 0000903423-14-000118
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140219
FILED AS OF DATE: 20140220
DATE AS OF CHANGE: 20140220
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONCERT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001367920
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-860-0045
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: CONCERT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36310
FILM NUMBER: 14631185
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
4
1
glaxo-concert.xml
OWNERSHIP DOCUMENT
X0306
4
2014-02-19
1
0001367920
CONCERT PHARMACEUTICALS, INC.
CNCE
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX,
X0
TW 89GS
UNITED KINGDOM
0
0
0
1
Former 10% Owner
Common Stock
2014-02-19
4
C
0
141592
A
141592
I
By S.R. One Limited
Common Stock
2014-02-19
4
C
0
1179941
A
1321533
I
By Glaxo Group Limited
Common Stock
2014-02-19
4
P
0
35000
14.00
A
1356533
I
By S.R. One Limited
Series C Convertible Preferred Stock
2014-02-19
4
C
0
800000
0
D
Common Stock
141592
0
I
By S.R. One Limited
Series D Convertible Preferred Stock
2014-02-19
4
C
0
6666667
0
D
Common Stock
1179941
0
I
By Glaxo Group Limited
The Series C Convertible Preferred Stock and Series D Convertible Preferred Stock of Concert Pharmaceuticals, Inc. (the "Issuer") automatically converted into Common Stock of the Issuer on a 1-for-5.65 basis upon the closing of the Issuer's initial public offering on February 19, 2014 without payment of consideration.
Shares are held by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
Shares are held by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.
Not applicable.
/s/ Simon Dingemans, Chief Financial Officer
2014-02-20